Who is affected by this change?

This affects Independence Blue Cross Oncology, Hematology, Rheumatology providers on Medicare Advantage plans.

When does this change take effect?

This change is effective Apr 1, 2026.

Back to dashboard

Medicare AdvantageCoverageLow impact

MA08.180, Axatilimab-csfr (Niktimvo™) for Intravenous Use

Independence Blue Cross·Oncology, Hematology, Rheumatology·Pharmacy

Effective date

Apr 1, 2026

We identified it

Jun 19, 2026

Days to comply

—

Summary

Medicare Advantage policy MA08.180 for Axatilimab-csfr (Niktimvo™) for intravenous use has been reissued and will become effective April 1, 2026. This appears to be a coverage policy update for this specialty pharmaceutical drug administered intravenously.

Action Required

Action needed

By March 15, 2026: Clinical and billing teams should review the updated MA08.180 policy for Axatilimab-csfr (Niktimvo™) coverage requirements at the provided URL. Update any prior authorization or documentation requirements for this IV specialty drug in billing systems and clinical protocols before the April 1, 2026 effective date.

Related policy hubs

Independence Blue Cross policies Oncology Hematology Rheumatology